Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 1, 2013, Pages 87-92

  Ippolito, Edy ^a   Cellini, Numa ^b   Digesù, Cinzia ^a   Cilla, Savino ^a   Mantini, Giovanna ^b   Balducci, Mario ^b   Di Lallo, Alessandra ^c   Deodato, Francesco ^a   Macchia, Gabriella ^a   Massaccesi, Mariangela ^a   Mattiucci, Gian Carlo ^b   Tagliaferri, Luca ^a   Piermattei, Angelo ^a   Cuscunà, Daniele ^c   Morganti, Alessio G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c A Cardarelli Hospital   (Italy)

Author keywords

Dose escalation; Intensity modulated radiotherapy; Postoperative; Prostate cancer

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; SKIN TOXICITY;

ADENOCARCINOMA; AGED; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PELVIS; POSTOPERATIVE PERIOD; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84873994939     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.10.005     Document Type: Article

References (37)

1. Morris M.M., Dallow K.C., Zietman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997, 38:731-736.
2. Pacholke H.D., Wajsman Z., Algood C.B., et al. Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival. Urology 2004, 64:982-986.
3. Stein A., deKernion J.B., Dorey F., et al. Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology 2002, 39:59-62.
4. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomized controlled Trial (EORTC trial 22911). Lancet 2005, 366:572-578.
5. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006, 296:2329-2335.
6. Swanson G.P., Goldman B., Tangen C.M., et al. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: Data from Southwest Oncology Group 8794. J Urol 2008, 180:2453-2457.
7. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
8. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose-response: Results of the M. D. Anderson phase III randomized trial Int. J Radiat Oncol Biol Phys 2002, 53:1097-1105.
9. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005, 294:1233-1239.
10. Eade T.N., Hanlon A.L., Horwitz E.M., et al. What dose of external beam radiation is high enough for prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:682-689.
11. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose-escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500.
12. Cozzarini C., Montorsi F., Fiorino C., et al. Need for high radiation dose (>70 Gy) in early postoperative irradiation after radical prostatectomy: A single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 2009, 75:966-974.
13. Feng M., Hanlon A.L., Pisansky T.M., et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:1417-1423.
14. Zelefsky M., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53:1111-1116.
15. Amer A.M., Mott J., Mackay R.I., et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2003, 56:199-207.
16. Bastasch M.D., Teh B.S., Mai W.Y., et al. Post-nerve sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: Effect on erectile function. Int J Radiat Oncol Biol Phys 2002, 54:101-106.
17. Teh B.S., Amosson C.M., Mai W.Y., et al. Intensity modulated radiation therapy (IMRT) in the management of prostate cancer. Cancer Invest 2004, 22:913-924.
18. Li X.A., Wang J.Z., Jursinic P.A., et al. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2005, 61:1251-1257.
19. Digesú C., Cilla S., De Gaetano A., et al. Postoperative intensity modulated radiation therapy in high risk prostate cancer: A dosimetric comparison. Med Dosim 2010, [Epub ahead of print].
20. Alongi F., Fiorino C., Cozzarini C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with postoperative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009, 93:207-212.
21. Fowler J., Chappell R., Ritter M. Is α/β for prostate cancer really low?. Int J Radiat Oncol Biol Phys 2001, 50:1021-1031.
22. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6. -13.
23. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose-escalation trial. Int J Radiat Oncol Biol Phys 2006, 64:518-526.
24. Martin J.M., Rosewall T., Bayley A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy fro localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1084-1089.
25. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer. Cleveland clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430.
26. Cagiannos I., Karakiewicz P., Eastham J.A., et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003, 170:1798-1803.
27. Roach M., Marquez C., You H., et al. Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1993, 28:33-37.
28. Barth P.G., Gerharz E.V., Ramaswamy A., et al. The influence of lymph node counts on the detection of pelvic lymph node metastasis in prostate cancer. Pathol Res Pract 1999, 195:633.
29. Poortmans P., Bossi A., Vandeputte K., et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007, 84:121-127.
30. Perez C.A., Brady L.W. Overview. Principles and Practices of Radiation Oncology, 2nd ed. 1992 1992, 1-63. Lippincott Company, Philadelphia. C.A. Perez, L.W. Brady (Eds.).
31. Glynne-Jones R., Sebag-Montefiore D., Maughan T.S., et al. A phase I dose-escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006, 17:50-56.
32. Morganti A.G., Balducci M., Salvati M., et al. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT in combination with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys 2010, 77:92-97.
33. Arbuck S.G. Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol 1996, 7:567-573.
34. Greene F.L., Page D.L., Fleming I.D., et al. AJCC (American Joint Committee on Cancer)-UICC (Union International Contre Cancer) Cancer Staging Manual 2002, Springer, New York, NY. 6th ed.
35. Arcangeli S., Saracino B., Petrongari M.G., et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 2007, 84:148-155.
36. Ost P., Fonteyne V., Villeirs G., et al. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: Clinical results in 104 patients. Eur J Urol 2009, 56:669-675.
37. Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 2002, 167:1681-1686.